These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 34838814)

  • 1. Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data.
    Lucidarme J; Bai X; Lekshmi A; Clark SA; Willerton L; Ribeiro S; Campbell H; Serino L; De Paola R; Holland A; Louth J; Ramsay ME; Ladhani SN; Borrow R
    J Infect; 2022 Feb; 84(2):136-144. PubMed ID: 34838814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020.
    Muzzi A; Lu M-C; Mori E; Biolchi A; Fu T; Serino L
    mSphere; 2024 Jun; 9(6):e0022024. PubMed ID: 38752729
    [No Abstract]   [Full Text] [Related]  

  • 4. 4CMenB journey to the 10-year anniversary and beyond.
    Abitbol V; Martinón-Torres F; Taha MK; Nolan T; Muzzi A; Bambini S; Borrow R; Toneatto D; Serino L; Rappuoli R; Pizza M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357924. PubMed ID: 38976659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of expanded
    Borrow R; Martinón-Torres F; Abitbol V; Andani A; Preiss S; Muzzi A; Serino L; Sohn WY
    Expert Rev Vaccines; 2023; 22(1):738-748. PubMed ID: 37622470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.
    Law DK; Lefebvre B; Gilca R; Deng S; Zhou J; De Wals P; Tsang RS
    BMC Microbiol; 2015 Jul; 15():143. PubMed ID: 26204985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB).
    Efron A; Biolchi A; Sorhouet Pereira C; Tomei S; Campos J; De Belder D; Moscoloni MA; Santos M; Vidal G; Nocita F; Vizzotti C; Pizza M
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288389. PubMed ID: 38111094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.
    McNamara LA; Shumate AM; Johnsen P; MacNeil JR; Patel M; Bhavsar T; Cohn AC; Dinitz-Sklar J; Duffy J; Finnie J; Garon D; Hary R; Hu F; Kamiya H; Kim HJ; Kolligian J; Neglia J; Oakley J; Wagner J; Wagner K; Wang X; Yu Y; Montana B; Tan C; Izzo R; Clark TA
    Pediatrics; 2015 May; 135(5):798-804. PubMed ID: 25917990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis.
    Savitskaya VY; Dolinnaya NG; Strekalovskikh VV; Peskovatskova ES; Snyga VG; Trefilov VS; Monakhova MV; Kubareva EA
    Med Sci (Basel); 2023 Dec; 11(4):. PubMed ID: 38132917
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review.
    Cinconze E; Rosillon D; Rappuoli R; Vadivelu K; Bekkat-Berkani R; Abbing-Karahagopian V
    Vaccine; 2023 Jul; 41(30):4347-4358. PubMed ID: 37321895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation.
    Kesanopoulos K; Bratcher HB; Hong E; Xirogianni A; Papandreou A; Taha MK; Maiden MCJ; Tzanakaki G
    PLoS One; 2018; 13(12):e0209919. PubMed ID: 30592763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.
    Marshall HS; Andraweera PH; Wang B; McMillan M; Koehler AP; Lally N; Almond S; Denehy E; A'Houre M; Giles LC; Flood L
    Hum Vaccin Immunother; 2021 May; 17(5):1450-1454. PubMed ID: 33428528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genomic epidemiology of
    Leong LEX; Coldbeck-Shackley RC; McMillan M; Bratcher HB; Turra M; Lawrence A; Kahler C; Maiden MCJ; Rogers GB; Marshall H
    Lancet Reg Health West Pac; 2024 Feb; 43():100966. PubMed ID: 38169944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversification in immunogenicity genes caused by selective pressures in invasive meningococci.
    Kremer PHC; Lees JA; Ferwerda B; Bijlsma MW; MacAlasdair N; van der Ende A; Brouwer MC; Bentley SD; van de Beek D
    Microb Genom; 2020 Sep; 6(9):. PubMed ID: 32776867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4CMenB Vaccination to Prevent Meningococcal B Disease in Vietnam: Expert Review and Opinion.
    Nguyen PNT; Thai PQ; Dien TM; Hai DT; Dai VTT; Luan NH; Mathur G; Badur S; Truyen DM; Le Minh NH
    Infect Dis Ther; 2024 Mar; 13(3):423-437. PubMed ID: 38430327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.
    Ladhani SN; White PJ; Campbell H; Mandal S; Borrow R; Andrews N; Bhopal S; Saunders J; Mohammed H; Drisdale-Gordon L; Callan E; Sinka K; Folkard K; Fifer H; Ramsay ME
    Lancet Infect Dis; 2024 Mar; ():. PubMed ID: 38521080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifecycle model-based evaluation of infant 4CMenB vaccination in the UK.
    Sevilla JP; Tortorice D; Kantor D; Regan J; Meszaros KH; Beck EC; Begum N; Bloom DE
    Eur J Health Econ; 2024 Jan; ():. PubMed ID: 38182698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of the 4CMenB vaccine in combating gonorrhoea: the need for nuance in interpreting the DOXYVAC trial.
    White PJ; Leng T; Nikitin D; Whittles LK
    Lancet Infect Dis; 2024 Jul; ():. PubMed ID: 39032496
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of Invasive Meningococcal Disease in Preterm Infants.
    Calvert A; Campbell H; Heath PT; Jones CE; Le Doare K; Mensah A; Ladhani S
    Open Forum Infect Dis; 2024 Apr; 11(4):ofae164. PubMed ID: 38665170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A National Advisory Committee on Immunization (NACI) update on invasive meningococcal disease (IMD) epidemiology and program-relevant considerations for preventing IMD in individuals at high risk of exposure.
    Pham-Huy A; Zafack J; Primeau C; Baclic O; Salvadori M; Deeks S
    Can Commun Dis Rep; 2023 Sep; 49(9):358-367. PubMed ID: 38463903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.